Botry Zen makes quiet entry on main board

Nearly 127,000 shares traded hands during the day, four times the daily volume when the stock was listed on the new capital market.

Forsyth Barr investment adviser Tom Bliss said there was some interest in the stock but its value was not helped by a reasonably large number of sellers.

Botry Zen has the world manufacturing and marketing rights to a biological control for the fruit-wasting botrytis fungus.

Company chairman Max Shepherd said he was comfortable with Botry Zen's position, saying it was poised to grow and expand.

Chief executive John Scandrett said the company would boost its profile and credibility as it sought business partners and markets around the world for Botry Zen.

The Dunedin manufacturing plant was working to get the product to Australia, the United States and Europe.

This is unlikely to be the last Dunedin biotechnology company to graduate from the unlisted to the main board.

Pharma Zen, which manufactures animal remedy products, has previously announced listing plans.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Botry-Zen calls in receivers